Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus ...

The combination showed efficacy exceeding that of either monotherapy ...

Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months ...

Promising trial results: AlloNK plus rituximab achieved a 71% ACR50 response rate in mid-stage testing for refractory rheumatoid arthritis, with no treatment-related serious adverse events. Regulatory ...

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in ...

Superior trial results: JNJ-4804 outperformed guselkumab or golimumab alone in achieving remission and endoscopic response in severe IBD patients. Safety profile holds: The combination therapy showed ...

On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...

Cellenkos receives US FDA clearance to initiate phase 1b/2a trial of CK0802 in steroid-refractory graft-versus-host disease: Houston Thursday, May 7, 2026, 18:00 Hrs [IST] Cellenk ...

Amandeep Salhotra, MD, discusses preclinical findings that could support the addition of a BCL2 inhibitor to address acute or ...

Cellenkos®, Inc., a clinical stage biotechnology company, pioneering allogeneic, tissue-targeted regulatory T cell (Treg) ...

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no pat ...

Johnson & Johnson (NYSE: JNJ) today announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 (IL-23) and tumor necrosis factor ...